Pfizer's latest COVID booster targets Omicron JN.1. Learn who should get it and why it’s essential for protection.

The shot was developed by Pfizer and targets the JN.1 sub-variant of Omicron. This is now the fifth iteration of the COVID vaccines, which have been updated regularly to keep up with the rapidly ...

Australia's Therapeutic Goods Administration has approved a new COVID booster by Pfizer targeting the JN.1 sub-variant of Omicron. Despite evolving variants, boosters remain crucial, especially for ...

Ongoing studies shows why covid 19 protection wanes over time. Know the factors behind waning immunity, why booster doses are ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an adapted version of the Nuvaxovid COVID-19 vaccine that targets the ...

The absolute number of COVID-19 deaths was three times higher than those from flu, but the case-fatality ratio was comparable ...

UK researchers have analysed the likely impact that a Covid booster shot will have on Omicron and say it could provide around ...

The study was based on outcomes seen among essential workers with COVID-19 infection from June 2021 to September 2022.

Booster doses of the original monovalent COVID-19 vaccine are associated with lower incidence of symptoms in health care personnel 6 weeks postinfection.

COVID-19 vaccination coverage has progressed unevenly throughout the world. Moreover, 1.01 and 1.43 doses for each person are ...

The vaccine is part of a recommended vaccine regimen for children ... and attempts to address the rise of FLiRT omicron ...